{"id":"W3179570450","doi":"10.1097/qad.0000000000003025","title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.","year":2022,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Rilpivirine; Tolerability; Regimen; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Adverse effect; Atlas (anatomy); Viral load; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006140266,0.001498294,0.001249214,0.0002994721,0.0004836017,0.001058472,0.0008398464,0.001052323,0.005789168],"category_scores_gemma":[0.003583969,0.0005078168,0.002067354,0.0003470866,0.0007318931,0.0008889096,0.0005989941,0.002723157,0.001325876],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007456793,"about_ca_system_score_gemma":0.001872783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008151516,"about_ca_topic_score_gemma":0.001802787,"domain_scores_codex":[0.9982828,0.0009605496,0.0001331192,0.000235665,0.0002232221,0.0001646596],"domain_scores_gemma":[0.9969838,0.0005616712,0.000949393,0.0003915718,0.0003095926,0.0008038988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8856658,0.03642998,0.01202624,0.0005120701,0.002263345,0.0002015611,0.0002401898,0.001828152,0.02004749,0.0001292947,0.003692932,0.03696311],"study_design_scores_gemma":[0.4047679,0.5255095,0.0509563,0.00007123269,0.001797222,0.0004020935,0.0001137705,0.001498375,0.008088643,0.0003205697,0.006386061,0.00008832443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841648,0.001044984,0.001314629,0.0002289681,0.0001381066,0.005780369,0.004700727,0.0001008427,0.002526599],"genre_scores_gemma":[0.9777104,0.0005803156,0.003789626,0.0006179339,0.0001004045,0.006618949,0.006891497,0.0000555207,0.00363535],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006140266,"threshold_uncertainty_score":0.03247321,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06818869719114717,"score_gpt":0.3697766567304088,"score_spread":0.3015879595392617,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}